Notice: This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AQXP vs. LGND, AKRO, AMPH, MIRM, BLTE, SUPN, GPCR, IRON, HRMY, and MNKDShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Ligand Pharmaceuticals (LGND), Akero Therapeutics (AKRO), Amphastar Pharmaceuticals (AMPH), Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Supernus Pharmaceuticals (SUPN), Structure Therapeutics (GPCR), Disc Medicine (IRON), Harmony Biosciences (HRMY), and MannKind (MNKD). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Ligand Pharmaceuticals Akero Therapeutics Amphastar Pharmaceuticals Mirum Pharmaceuticals Belite Bio Supernus Pharmaceuticals Structure Therapeutics Disc Medicine Harmony Biosciences MannKind Aquinox Pharmaceuticals (NASDAQ:AQXP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment. Does the media favor AQXP or LGND? In the previous week, Ligand Pharmaceuticals had 23 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 23 mentions for Ligand Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.87 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Ligand Pharmaceuticals Positive Which has more risk & volatility, AQXP or LGND? Aquinox Pharmaceuticals has a beta of -7.37, meaning that its share price is 837% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Do analysts rate AQXP or LGND? Ligand Pharmaceuticals has a consensus price target of $147.00, indicating a potential upside of 28.23%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, AQXP or LGND? Ligand Pharmaceuticals has higher revenue and earnings than Aquinox Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M21.32-$31.58MN/AN/ALigand Pharmaceuticals$152.42M14.21$52.15M$2.5145.67 Does the MarketBeat Community favor AQXP or LGND? Ligand Pharmaceuticals received 252 more outperform votes than Aquinox Pharmaceuticals when rated by MarketBeat users. However, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 70.73% of users gave Ligand Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% Ligand PharmaceuticalsOutperform Votes55170.73% Underperform Votes22829.27% Is AQXP or LGND more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Aquinox Pharmaceuticals' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat Aquinox Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Ligand Pharmaceuticals 29.68%4.95%4.39% Do institutionals & insiders hold more shares of AQXP or LGND? 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryLigand Pharmaceuticals beats Aquinox Pharmaceuticals on 14 of the 16 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.95M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales21.32196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book7.335.094.784.78Net Income-$31.58M$151.83M$120.31M$225.60M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$22.64+2.6%N/A+53.1%$532.95M$25M0.008LGNDLigand Pharmaceuticals4.9822 of 5 stars$115.29-7.6%$144.83+25.6%+61.9%$2.18B$131.31M49.7380Analyst RevisionAKROAkero Therapeutics4.09 of 5 stars$31.07-0.1%$46.83+50.7%+31.5%$2.17BN/A0.0030Insider TradeAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$44.02+0.5%$60.33+37.1%-34.7%$2.12B$644.40M14.601,761MIRMMirum Pharmaceuticals4.0978 of 5 stars$43.17-3.4%$57.73+33.7%+33.5%$2.07B$186.37M0.00140BLTEBelite Bio2.0968 of 5 stars$67.25-9.6%$89.00+32.3%+43.1%$2.06BN/A-60.6820SUPNSupernus Pharmaceuticals2.1946 of 5 stars$37.10-0.2%$36.00-3.0%+23.8%$2.05B$607.52M34.74580GPCRStructure Therapeutics2.3688 of 5 stars$35.25+5.7%$85.67+143.0%-15.5%$2.02BN/A0.00136Analyst ForecastNews CoverageGap UpIRONDisc Medicine3.4762 of 5 stars$64.82+4.0%$85.80+32.4%+10.7%$1.93BN/A-16.2978Insider TradeHRMYHarmony Biosciences4.7853 of 5 stars$33.67-0.3%$47.00+39.6%+6.2%$1.92B$582.02M16.00200Analyst ForecastAnalyst RevisionMNKDMannKind3.1916 of 5 stars$6.72-1.2%$8.67+29.0%+100.3%$1.85B$198.96M97.14400Analyst UpgradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies LGND Competitors AKRO Competitors AMPH Competitors MIRM Competitors BLTE Competitors SUPN Competitors GPCR Competitors IRON Competitors HRMY Competitors MNKD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AQXP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQXP Stock Alerts